Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Janux Therapeutics, Inc.NASDAQ: JANX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $3.73M, compared with $0 a year earlier. Trailing-twelve-month revenue was $21.61M. Over 3 fiscal years it compounded at +5.1% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 11 analysts of $27.98M (+179.8%) for the fiscal year ending Dec 2026, a step up from the -5.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.73M-52.6% QoQ
Last fiscal yearDec 2025
$10M-5.6% YoY
LTMMar 2026
$21.61M+131.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-5.6%+179.8%+185.3 pp
3-year CAGR+5.1%-10.3%-15.4 pp
5-year CAGR+61.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
10M USD
Year-over-year change
-5.6%
4-year CAGR
+28.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +131.5% is the highest of 9, against a peer median of -75.0%.
  • Over three fiscal years its annual growth of +5.1% compares with a peer median of +6.3%.
JANX Competitors
Revenue for JANX and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026$1.36B USD+49.5%+106.4%
MGNXMacroGenics, Inc.LTM Mar 2026$157.08M USD+3.1%-0.1%
STROSutro Biopharma, Inc.LTM Mar 2026$99.61M USD+49.9%+14.8%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-34.6%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.54M USD-75.9%+12.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$21.61M USD+131.5%+5.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$112K USD-95.7%-14.0%
IMNMImmunome, Inc.LTM Sep 2026$0 USD-100.0%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 USD——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding JANX) —-75.0%+6.3%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.